Search Protocols under revision. Back New search Go to resultsDiseaseMain groupPediatric Oncology and HematologySolid TumorsProtocol groupNeuro-OncologyRare Diseases (ped.)DiseaseNeurofibromatosisSubgroupPlexiform Neurofibromatype 1ICD10Q85.0MeSHNeurofibroma, PlexiformNeurofibromatosis 1SequenceAntineoplastic therapySubstanceMirdametinibSelumetinibSubstanceMirdametinibSelumetinibSubstanceMirdametinibSelumetinibSubstanceMirdametinibSelumetinibNo. Substances1 RadiotherapySupportive therapySubstanceSubstanceSubstanceSubstanceNo. SubstancesProtocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlCardiotoxicityConstipationDiarrheaEmetogenicityExanthema, AcneiformHypocalcemiaIncrease AminotransferasesIncrease Creatinine PhosphokinaseMucositisNail ChangesNeutropeniaPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µlVomiting only studiesPublicationAuthorGross AMMoertel CDiseaseNeurofibromatose Typ 1, Plexiforme Neurofibrome nicht operabelNeurofibromatose Typ 1, Plexiforme Neurofibrome nicht operabel, <18 JahreOriginNational Institutes of Health, BethesdaThe ReNeu Trial InvestigatorsProtocols in Revision 2 protocols foundMirdametinib 2, Neurofibromatosis (PID2983 V1.0)Selumetinib 25, neurofibromatosis (PID2226 V1.0)
